Summit Securities Group LLC Reduces Stake in Merck & Co., Inc. $MRK

Summit Securities Group LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 66.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,800 shares of the company’s stock after selling 5,438 shares during the quarter. Summit Securities Group LLC’s holdings in Merck & Co., Inc. were worth $360,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. D.A. Davidson & CO. increased its stake in Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after buying an additional 24,576 shares during the period. Pinnbrook Capital Management LP grew its stake in Merck & Co., Inc. by 95.2% in the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after acquiring an additional 11,355 shares in the last quarter. Cibc World Market Inc. increased its position in shares of Merck & Co., Inc. by 32.6% during the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after acquiring an additional 320,143 shares during the period. Handelsbanken Fonder AB increased its position in shares of Merck & Co., Inc. by 13.9% during the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after acquiring an additional 224,752 shares during the period. Finally, Panagora Asset Management Inc. raised its stake in shares of Merck & Co., Inc. by 410.5% during the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after acquiring an additional 567,249 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Trading Down 1.9%

MRK opened at $149.25 on Friday. The firm has a market cap of $368.23 billion, a price-to-earnings ratio of 119.40, a PEG ratio of 6.56 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $153.50. The stock has a fifty day moving average price of $127.43 and a 200-day moving average price of $121.01.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analysts Set New Price Targets

MRK has been the topic of several research analyst reports. CICC Research started coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective on the stock. Argus increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $142.10.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna’s Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.